Companies › K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
1 active drug program in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Azenosertib Serine/threonine-protein kinase WEE1 inhibitor | WEE1 | Phase 3 | Ovarian Cancer; High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Solid Tumor; Uterine Serous Carcinoma … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05128825 | Azenosertib | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Oncology | Dec 2026 |
| NCT06369155 | Azenosertib | Phase 2 | Uterine Serous Carcinoma | Oncology | Jan 2027 |
| NCT06364410 | Azenosertib | Phase 1 | Clinical Stage III Gastric Cancer AJCC v8 | Oncology | Jul 2027 |
| NCT07546500 | Azenosertib | Phase 3 | Ovarian Cancer | Oncology | May 2028 |
| NCT04516447 | Azenosertib | Phase 1 | Solid Tumor | Oncology | Jun 2028 |
Maia Biotechnology FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio pharmaand
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.